التفاصيل البيبلوغرافية
| العنوان: |
Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels. |
| المؤلفون: |
Gregory Hess, Jerrold Hill, Jeffrey Clough, Scott Hulnick, Robert J. Nordyke |
| المصدر: |
Current Medical Research & Opinion; Mar2008, Vol. 24 Issue 3, p815-819, 5p |
| مصطلحات موضوعية: |
ERYTHROPOIESIS, HEMATOPOIESIS, DRUG side effects, ANEMIA, BONE marrow diseases, MYELODYSPLASTIC syndromes |
| مستخلص: |
Objective: Previous labeling and guidelines recommended initiating erythropoiesis agents (ESAs) for chemotherapy-induced anemia (CIA) at hemoglobin (Hb) levels < 11 g/dL, maintaining near 12 g/dL, and withholding at ≥ 13 g/dL. This study analyzed adherence with recommendations in administration of darbepoetin (DA) to cancer patients.Design, setting, and participants: Retrospective analysis of Hb levels at which DA was administered using Varian electronic medical records (EMRs). The dataset comprises 141 694 cancer patients from 82 sites across 13 states. The study evaluated DA administrations with respect to recorded Hb for 8988 patients from 1/1/05 to 5/31/07.Main outcome measures: Proportion of DA admin istrations at Hb ≥ 12 and Hb ≥ 13 g/dL. Hb level was analyzed for all administrations, stratified by year and anemia type (CIA, anemia-of-cancer, and myelodysplastic syndrome).Results: There were 51 111 DA administrations with Hb results. The proportion of administrations at Hb ≥ 12 g/dL was 7.2% and at Hb ≥ 13 g/dL was 0.6%, and for CIA 6.9%/0.6%, anemia of cancer (AOC) 8.8%/0.8%, and myelodysplastic syndrome (MDS) 6.5%/0.6%. The propor tion of all DA administrations at Hb ≥ 12 g/dL and ≥ 13 g/dL declined from 8.6% to 5.3% (p < 0.0001) and from 0.7% to 0.4% (p < 0.0007), respectively during 1/1/05–5/31/07.Conclusions: In this population, DA administration at Hb ≥ 12 g/dL and Hb ≥ 13 g/dL occurred in 7.2% and 0.6% of administrations, respectively, a ≈ 93% adherence rate with recommendations. Further research is required to under stand dose titrations at Hb 12–13 g/dL, and whether similar patterns are observed for other ESAs, and in other practice settings. This study provides context for the debate regarding the utilization, benefits and risks of ESAs in cancer patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Medical Research & Opinion is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher 
Full Text Finder